TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37566253
Drug: Community-based multidisciplinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based multidisciplinary group intervention program (10-week duration, including twice-weekly exercise sessions and weekly education sessions)
Study: 37566578
Drug: OT infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OT infusion at 3.3 mU/min in women with morbid obesity
Study: 37566578
Drug: OT infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OT infusion in women with non-obesity and obesity
Study: 37566578
Drug: OT infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OT infusion in women with obesity
Study: 37566578
Drug: OT infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OT infusion in women with morbid obesity
Study: 37567205
Drug: Long-acting cabotegravir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting cabotegravir (600 mg) plus rilpivirine (900 mg) dosed intramuscularly every 2 months
Study: 37567205
Drug: Bictegravir (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg) taken daily
Study: 37567750
Drug: Rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5 mg two times a day
Study: 37568076
Drug: One-Level ESPB
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-Level ESPB (n=30) with 30 ml 0.25% bupivacaine
Study: 37568076
Drug: Bi-Level ESPB
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bi-Level ESPB (n=30) with 15 ml 0.25% bupivacaine at T4 and T6 levels
Study: 37568158
Drug: Bovine colostrum
Normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine colostrum (20 g thrice a day for 4 weeks)
Study: 37568381
Drug: Oral carbohydrate
Normalized name: omega-3 carboxylic acids Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral carbohydrate 2 hours before elective cesarean delivery
Study: 37568391
Drug: Posterior tibial
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior tibial nerve stimulation (PTNS) with duloxetine (30 mg/day)
Study: 37568391
Drug: Duloxetine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (30 mg/day) only
Study: 37568622
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg intravenously every 21 days
Study: 37570430
Drug: Educational solutions
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational solutions (360 V, VR, web-based information, psychoeducation)
Study: 37572086
Drug: Ibrutinib maintenance
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib maintenance (560 mg/d)
Study: 37572581
Drug: Locally produced
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Locally produced fish-based ready-to-use therapeutic food (L-RUTF)
Study: 37572581
Drug: Both L-RUTF
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both L-RUTF and S-RUTF
Study: 37572659
Drug: ChAd63-MVA RH5
Normalized name: MVA
DrugBank: Modified vaccinia ankara (DB15483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAd63-MVA RH5 vaccine
Study: 37573322
Drug: CR500® treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR500® treatment applied topically twice a week for 4 weeks
Study: 37573322
Drug: CR500® treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR500® treatment
Study: 37573421
Drug: Weekly multi-disciplinary
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly multi-disciplinary team-based case consultation and peer-to-peer sharing of emerging best practices (teleECHO) with monthly interactive webinars and quarterly short courses
Study: 37573421
Drug: Monthly interactive
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly interactive webinars and quarterly short courses
Study: 37573936
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) (25.0% of patients, mean duration 26.2 ± 23.2 days)
Study: 37573936
Drug: Any other
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any other anticoagulants (6.2%)
Study: 37573936
Drug: No anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anticoagulant (6.7%)
Study: 37573968
Drug: Physician-guided discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician-guided discontinuation
Study: 37574132
Drug: Brigatinib 180
Normalized name: brigatinib 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brigatinib 180 mg once daily (7-d lead-in, 90 mg)
Study: 37574132
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (exploratory analysis)
Study: 37574780
Drug: Ad-HSV1-TK/GCV and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad-HSV1-TK/GCV and Ad-Flt3L gene therapy
Study: 37574821
Drug: Tandem infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tandem infusions of MIITOP
Study: 37574821
Drug: Tandem infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tandem infusions of MIITOP followed by busulfan-melphalan
Study: 37574953
Drug: lanadelumab 300
Normalized name: lanadelumab 300 mg in 2 mL SUBCUTANEOUS SOLUTION [TAKHZYRO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: lanadelumab 300 mg every 2 weeks subcutaneously for 52 weeks (with possible reduction to 300 mg every 4 weeks during the second 26-week period if well-controlled)
Study: 37574953
Drug: lanadelumab 300
Normalized name: lanadelumab 300 mg in 2 mL SUBCUTANEOUS SOLUTION [TAKHZYRO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: lanadelumab 300 mg every 2 weeks subcutaneously for 52 weeks
Study: 37575149
Drug: Emollient+ used
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emollient+ used at least once daily
Study: 37575420
Drug: VR-guided meditation
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VR-guided meditation intervention (8 sessions of 15-min each, twice weekly for 4 weeks)
Study: 37576973
Drug: Extracellular vesicle-enriched
Normalized name: Bos taurus testicle preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extracellular vesicle-enriched preparations from participants with T1D
Study: 37576973
Drug: Extracellular vesicle-enriched
Normalized name: Bos taurus testicle preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extracellular vesicle-enriched preparations from healthy normal volunteers (Controls)
Study: 37577112
Drug: Sotrovimab 500
Normalized name: sotrovimab 500 MG in 8 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotrovimab 500 mg IM injection
Study: 37577112
Drug: Sotrovimab 250
Normalized name: SOTROVIMAB
DrugBank: Sotrovimab (DB16355)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Sotrovimab 250 mg IM injection
Study: 37577293
Drug: Ephedrine usage,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine usage, hypothermia, need for additional analgesics, nausea, and vomiting
Study: 38306745
Drug: Delandistrogene moxeparvovec
Normalized name: Delandistrogene moxeparvovec
DrugBank: Delandistrogene moxeparvovec (DB16802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delandistrogene moxeparvovec gene therapy
Study: 37577796
Drug: NCTF®135HA injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCTF®135HA injections plus twice-daily anti-aging moisturizer cream
Study: 37577796
Drug: Anti-aging moisturizer
Normalized name: AVOBENZONE 3 g in 100 mL / HOMOSALATE 8 g in 100 mL / OCTINOXATE 7.5 g in 100 mL / OCTISALATE 5 g in 100 mL TOPICAL CREAM [MURAD - ANTI-AGING MOISTURIZER SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-aging moisturizer cream alone
Study: 37577798
Drug: Mepolizumab (anti-IL-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab (anti-IL-5 therapy)
Study: 37577801
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (1 Hz rTMS)
Study: 37577817
Drug: PegIFNα-2b treatment
Normalized name: Interferon α-2b
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PegIFNα-2b treatment for 68 weeks
Study: 37577817
Drug: PegIFNα-2b-based immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFNα-2b-based immunotherapy (two cycles with GM-CSF and vaccine treatment)
Study: 37577967
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow aspirate concentrate treatment
Study: 37578052
Drug: Wireless motility
Normalized name: careless weed pollen extract
DrugBank: Amaranthus palmeri pollen (DB10459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wireless motility capsule test
Study: 37578099
Drug: Burosumab treatment
Normalized name: Burosumab
DrugBank: Burosumab (DB14012)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Burosumab treatment for 48 weeks
Study: 37578099
Drug: Burosumab treatment
Normalized name: Burosumab
DrugBank: Burosumab (DB14012)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Burosumab treatment for 144 weeks (exploratory analysis)
Study: 37578099
Drug: Burosumab treatment
Normalized name: Burosumab
DrugBank: Burosumab (DB14012)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Burosumab treatment for 144 weeks (SF-36 v2 scores)
Study: 37578113
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis for a duration of 24 hours
Study: 37578113
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis for a duration longer than 24 hours
Study: 37578188
Drug: Glucose-lowering therapies
Normalized name: biguanide blood glucose lower drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-lowering therapies
Study: 37578437
Drug: Facet Joint
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facet Joint Injection (FIJ)
Study: 37578791
Drug: Ginkgo diterpene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo diterpene lactone meglumine (GDLM) administered once daily via intravenous infusion for 14 days.
Study: 37578791
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered once daily via intravenous infusion for 14 days.
Study: 37579053
Drug: Leflutrozole 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leflutrozole 0.1 mg
Study: 37579053
Drug: Leflutrozole 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leflutrozole 0.3 mg
Study: 37579053
Drug: Leflutrozole 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leflutrozole 1.0 mg
Study: 37579053
Drug: Leflutrozole (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leflutrozole (all doses)
Study: 37579053
Drug: Leflutrozole (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leflutrozole (0.1 mg, 0.3 mg, 1.0 mg)
Study: 37579116
Drug: Exenatide 2
Normalized name: exenatide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 2 mg subcutaneously once-weekly for 6 weeks
Study: 37579116
Drug: Standard individual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard individual drug counseling
Study: 37579773
Drug: MenABCWY vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenABCWY vaccine (0.5 mL, months 0 and 6)
Study: 37579773
Drug: MenB-FHbp and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenB-FHbp and MenACWY-CRM (two doses of MenB-FHbp and one dose of MenACWY-CRM)
Study: 37580498
Drug: MP-AzeFlu nasal
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MP-AzeFlu nasal spray (one spray per nostril twice daily for 14 days)
Study: 37580498
Drug: Azelastine hydrochloride
Normalized name: Azelastine Hydrochloride
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azelastine hydrochloride nasal spray (AZE)
Study: 37580498
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate nasal spray (FLU)
Study: 37580498
Drug: MP-AzeFlu nasal
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MP-AzeFlu nasal spray
Study: 37580661
Drug: Anlotinib 8
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib 8 mg once daily and Fluzoparib 150 mg twice daily until disease progression or intolerable toxicity
Study: 37580663
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of enteral cholecalciferol (10,000 IU/kg, maximum of 400,000 IU)
Study: 37580773
Drug: Ribociclib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib plus endocrine therapy (ET) including letrozole, fulvestrant, or tamoxifen with goserelin.
Study: 37581593
Drug: Mosunetuzumab with
Normalized name: Mosunetuzumab
DrugBank: Mosunetuzumab (DB15434)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosunetuzumab with CHOP chemotherapy
Study: 37581616
Drug: Physician's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's choice of chemotherapy (PCC)
Study: 37581673
Drug: Vaginal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal estrogen (1 g of conjugated estrogen cream, 0.625 mg/g)
Study: 37581981
Drug: Midostaurin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midostaurin (50 mg twice daily) plus chemotherapy (idarubicin or daunorubicin) for 21 days
Study: 37581981
Drug: Midostaurin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midostaurin (50 mg twice daily) plus chemotherapy
Study: 37582096
Drug: Fruit and
Normalized name: elderberry fruit and flower 460 mg-115 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruit and 100% fruit juice (low doses, up to or less than ~10% E)
Study: 37582096
Drug: Mixed sources
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed sources (with sugar-sweetened beverages [SSBs]) at high doses (up to 23%)
Study: 37582170
Drug: Tricuspid transcatheter
Normalized name: Maclura tricuspidata whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricuspid transcatheter edge-to-edge repair with the TriClip implant
Study: 37582474
Drug: Manual physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual physical therapy (3 sessions)
Study: 37582633
Drug: Recreational drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recreational drug use (positive test for recreational drugs)
Study: 37582633
Drug: Multiple drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple drug detection (28% of positive patients)
Study: 37582633
Drug: No recreational
Approvals — FDA: no, EMA: no, PMDA: no
Description: No recreational drug use (negative test)
Study: 37582730
Drug: Coronary catheterization
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coronary catheterization (CC) procedure once
Study: 37582730
Drug: Coronary catheterization
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coronary catheterization (CC) procedure twice
Study: 37582730
Drug: Coronary catheterization
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coronary catheterization (CC) procedure
Study: 37582952
Drug: Elranatamab (subcutaneous,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elranatamab (subcutaneous, once weekly after two step-up priming doses)
Study: 37582952
Drug: Elranatamab (biweekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elranatamab (biweekly dosing after six cycles for persistent responders)
Study: 37582952
Drug: Elranatamab (overall
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elranatamab (overall treatment)
Study: 37582952
Drug: Elranatamab (biweekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elranatamab (biweekly dosing)
Study: 37584207
Drug: Dual-therapy sirolimus-eluting
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dual-therapy sirolimus-eluting and CD34 antibody-coated COMBO stent (DTS)
Study: 37584254
Drug: RSV 10
Normalized name: RSV-IGIV
DrugBank: Respigam (DB17765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSV 10 mg/AML 5 mg
Study: 37584254
Drug: RSV 20
Normalized name: RSV-IGIV
DrugBank: Respigam (DB17765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSV 20 mg/AML 5 mg
Study: 37584254
Drug: ATV 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATV 20 mg/AML 5 mg
Study: 37584292
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for refractory chronic GVHD
Study: 37584344
Drug: Standard vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard vaccine
Study: 37584609
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance individuals
Study: 37584898
Drug: Triptorelin pamoate
Normalized name: Triptorelin Pamoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin pamoate 15 mg administered on day 1 and at months 3, 6, and 9
Study: 37585243
Drug: Self-administered web-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered web-based dietary recall
Study: 37585243
Drug: Interviewer-administered 24-hour
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interviewer-administered 24-hour dietary recall
Study: 37585569
Drug: Two-phased telehealth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-phased telehealth model for PTSD treatment
Study: 37585628
Drug: GNT0003 (gene
Approvals — FDA: no, EMA: no, PMDA: no
Description: GNT0003 (gene therapy) - higher dose
Study: 37585628
Drug: GNT0003 (gene
Approvals — FDA: no, EMA: no, PMDA: no
Description: GNT0003 (gene therapy) - lower dose
Study: 37585628
Drug: GNT0003 (gene
Approvals — FDA: no, EMA: no, PMDA: no
Description: GNT0003 (gene therapy)
Study: 37585627
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy alone (no radiotherapy)
Study: 37586052
Drug: Vibegron treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibegron treatment, dosage and duration not specified
Study: 37586317
Drug: TAEST16001 T
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAEST16001 T cell therapy after dose-reduced lymphodepletion with cyclophosphamide (15 mg/kg/day × 3 days) and fludarabine (20 mg/m2/day)
Study: 37586350
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (n = 40)
Study: 37586350
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (n = 26)
Study: 37586475
Drug: Mepolizumab (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab (100 mg subcutaneously every 4 weeks for 52 weeks)
Study: 37586560
Drug: Bi-weekly home
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bi-weekly home food delivery from the local food bank
Study: 37586560
Drug: Bi-weekly financial
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bi-weekly financial assistance with healthy food access navigation
Study: 37586845
Drug: Colchicine treatment
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine treatment 0.5 mg two times per day
Study: 37586862
Drug: biomodulation protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: biomodulation protocol (cryobiomodulation, photobiomodulation, electrobiomodulation) administered during the first 6 weeks after surgery
Study: 37586906
Drug: Intramuscular fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular fat fraction (IMFF) ≥ 15%
Study: 37587184
Drug: IV caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV caffeine 20 mg/kg followed by up to two daily doses of 5 mg/kg
Study: 37587184
Drug: IV caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV caffeine 20 mg/kg followed by up to two daily doses of 10 mg/kg
Study: 37587323
Drug: HCV cure
Normalized name: Cocci-Cure C for Calves
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV cure (DAAs treatment)
Study: 37587492
Drug: Intravenous arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous arginine therapy (200 mg/kg loading dose, max 20 g; followed by 100 mg/kg three times a day, max 10 g)
Study: 37587492
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline loading dose followed by normal saline three times a day)
Study: 37587502
Drug: FLYSYN (Fc-optimized
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLYSYN (Fc-optimized antibody directed to FLT3/CD135), administered intravenously at different dose levels (0.5 mg/m² in cohort 1-5)
Study: 37587502
Drug: FLYSYN (Fc-optimized
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLYSYN (Fc-optimized antibody directed to FLT3/CD135)
Study: 37587552
Drug: electronically delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: electronically delivered Cognitive Behavioral Therapy (e-CBT) program
Study: 37587580
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) with aspirin and ticagrelor
Study: 37587591
Drug: Low-dose colchicine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose colchicine (0.6 mg daily) with ticagrelor or prasugrel
Study: 37587734
Drug: Ultrasound-guided selective
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided selective supraclavicular nerve block with 0.1 mL/kg of 0.5% ropivacaine (SSCNB group)
Study: 37588266
Drug: Weight-adjusted dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-adjusted dosing of fibrinogen concentrate